Clinical trials: Non-Diabetic
Non-Alcoholic Fatty Liver Disease
Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)
This extension study will assess the safety and effects of 24 weeks of treatment with ALT-801 in diabetic and non-diabetic subjects with overweight and obesity and non-alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT05292911
- Testing
- ALT-801
- Where
- 13 sites in United States
- Volunteers
- 64 people
- Sponsor
- Altimmune, Inc.
Diabetes, Diabetes Mellitus, Type 2
Observational Study in Type 2 Diabetics Treated by an Intensive Insulin Treatment of Levemir®
This study is conducted in Europe. The aim of this observational study is to gain practical experience with once daily Levemir® administration in type 2 diabetes patients who were previously treated with NPH insulins (e.g.
- Trial name
- LITHULEV1 (NCT00806897)
- Testing
- insulin detemir
- Where
- Lithuania
- Volunteers
- 74 people
- Sponsor
- Novo Nordisk A/S
Non-diabetic Chronic Kidney Disease
A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease
Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial treatment, finerenone, is being developed to help people who have long lasting kidney disease…
- Trial name
- FIND-CKD (NCT05047263)
- Testing
- Finerenone (BAY94-8862)
- Where
- 326 sites in United States, Argentina and 22 more
- Volunteers
- 1,584 people
- Sponsor
- Bayer
Wounds and Injuries, Burns
ACTICOAT™ for the Treatment of Burns and Chronic Wounds
The aim of the study is to evaluate participant reported quality of life, safety, and overall performance with ACTICOAT in a clinical setting.
- Conditions
- Wounds and Injuries, Burns, Pressure Ulcer, Foot Ulcer
- Trial name
- NCT02852148
- Testing
- ACTICOAT
- Where
- 3 sites in United Kingdom
- Volunteers
- 25 people
- Sponsor
- Smith & Nephew, Inc.
Dyslipidemia, Type 2 Diabetes Mellitus
Management of Dyslipidemia in Adult Type 2 Diabetes Patients in India
The purpose of study to assess the control of dyslipidemia in the Indian diabetic population treated with any hypolipidemic agent.
- Trial name
- SOLID (NCT01292018)
- Volunteers
- 5,400 people
- Sponsor
- AstraZeneca
Diabetic Peripheral Neuropathic Pain
A Study of Duloxetine (LY248686) in Participants With Diabetic Peripheral Neuropathic Pain (DPNP)
The main purpose of this study is to evaluate the effectiveness and safety of the study drug known as duloxetine in participants with diabetic peripheral neuropathic pain.
- Trial name
- NCT02417935
- Testing
- Duloxetine, Pregabalin
- Volunteers
- 304 people
- Sponsor
- Eli Lilly and Company
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Evaluate Insulin in the Blood After Inhalation of a Dry Powder Insulin Formulation (Called Technosphere®/Insulin) in Non-diabetic Patients With & Without Chronic Obstructive Pulmonary Disease (COPD)
Trial will include 40 subjects and consists of 3 visits: Screening, Treatment and Follow up. A euglycemic clamp procedure and Technosphere®/Insulin (T/I) administration will occur at Visit 2 for both COPD and non COPD subjects.
- Trial name
- NCT01021891
- Testing
- Technosphere®/Insulin
- Where
- 5 sites in United States, Austria and 2 more
- Volunteers
- 39 people
- Sponsor
- Mannkind Corporation
Overweight or Obesity
A Study of TG103 Injection in Non-diabetic Overweight or Obesity
This study is a multicenter, randomized, double-blind, placebo-controlled, parallel phase 3 study to evaluate efficacy, safety, pharmacokinetics characteristics and immunogenicity of TG103 injection, a GLP-1 receptor agonist, for…
- Trial name
- NCT05997576
- Testing
- TG103 22.5 mg
- Where
- China
- Volunteers
- 675 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Diabetic Foot Ulcers (DFUs)
Clinical Trial Evaluating an Amnion Membrane Allograft for Use in the Management of Non- Healing Diabetic Foot Ulcers Versus Standard Of Care
The main purpose of this research study is to compare the proportion of wound closure in subjects that receive E-GRAFT™ with Standard of Care (SOC) versus FIBRACOL™ with SOC.
- Trial name
- NCT06767501
- Testing
- E-GRAFT ™, FIBRACOL™
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Skye Biologics Holdings, LLC